ruzasvir
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02076100)
Timeline
Indications
Mechanism of action
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
- Nonstructural protein 5AINHIBITOR
Nonstructural protein 5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3c(c2)O[C@@H](c2cnc(C4CC4)s2)n2c-3cc3cc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C- Mol. weight
- 929.12 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833385 ↗
- ChEMBLCHEMBL3971095 ↗
Also known as
- ruzasvir
- ruzasvir
- ruzasvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06921941 | Phase 1 | Apr 8, 2025 | Atea Pharmaceuticals, Inc. |
| NCT06356194 | Phase 1 | Apr 15, 2024 | Atea Pharmaceuticals, Inc. |
| NCT02956629 | Phase 2 | Nov 16, 2016 | Merck |
| NCT02759315 | Phase 2 | May 3, 2016 | Merck |
| NCT02666352 | Phase 1 | Jan 22, 2016 | Merck |
| NCT02332720 | Phase 2 | Jan 28, 2015 | Merck |
| NCT02332707 | Phase 2 | Jan 22, 2015 | Merck |
| NCT02076100 | Phase 1 | Mar 1, 2014 | Merck |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 6 | 6 | 2 | 2014 |
| Atea Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2024 |
2 organizations
Page 1 / 1